Earnings Releases·Nov 5, 2026, 6:02 AM ET

Prestige Consumer Healthcare Inc. — Fiscal 2027 Second Quarter Earnings Summary

Q2 2027 revenue rose 22.7% year-over-year to $336.3 million, though organic revenue declined 1.6%; full-year adjusted diluted EPS guidance was lowered to $4.48–$4.55 from $4.55–$4.65, and revenue guidance was reduced to $1,280–$1,290 million from $1,290–$1,315 million.
Reported net income for the first six months fell to $54.5 million ($1.14 diluted EPS) from $89.7 million ($1.81 diluted EPS) in the prior year, while adjusted net income for the period increased slightly to $100.3 million ($2.11 adjusted diluted EPS) from $99.9 million.
Full-year adjusted free cash flow guidance was reduced to $265 million or more from $270 million or more, primarily due to expected production variability at the Pillar5 facility limiting Clear Eyes® availability in the second half.
Acquisitions of the Breathe Right® portfolio and LaCorium Health contributed $65.1 million to Q2 revenue and $71.0 million to the first six months revenue, with management maintaining a long-term outlook of approximately 10% annual revenue growth and nearly $900 million in aggregate free cash flow over the next three years.
The company issued $400 million in new senior notes due 2034 in July 2026, replacing debt previously due in fiscal 2028, and recorded a $1.36 million loss on debt extinguishment during the first six months of 2027.